|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
PLENARY PAPER
From the Scott-Ritchey Research Center and Department
of Clinical Sciences. College of Veterinary Sciences, Auburn
University, AL; Departments of Pediatrics and Pathology, University of
Pennsylvania Medical Center and The Children's Hospital of
Philadelphia; and Department of Laboratory Medicine and Pathology,
University of North Carolina, Chapel Hill.
Hemophilia B is an X-linked coagulopathy caused by absence of
functional coagulation factor IX (FIX). Using adeno-associated virus (AAV)-mediated, liver-directed gene therapy, we achieved long-term (> 17 months) substantial correction of canine
hemophilia B in 3 of 4 animals, including 2 dogs with an FIX null
mutation. This was accomplished with a comparatively low dose of
1 × 1012 vector genomes/kg. Canine FIX (cFIX) levels
rose to 5% to 12% of normal, high enough to result in nearly complete
phenotypic correction of the disease. Activated clotting times and
whole blood clotting times were normalized, activated partial
thromboplastin times were substantially reduced, and anti-cFIX was not
detected. The fourth animal, also a null mutation dog, showed transient expression (4 weeks), but subsequently developed neutralizing anti-cFIX
(inhibitor). Previous work in the canine null mutation model has
invariably resulted in inhibitor formation following treatment by
either gene or protein replacement therapies. This study demonstrates
that hepatic AAV gene transfer can result in sustained therapeutic
expression in a large animal model characterized by increased risk of a
neutralizing anti-FIX response.
(Blood. 2002;99:2670-2676) Hemophilia B is a sex-linked bleeding disorder
caused by a deficiency of functional coagulation factor IX (FIX).
Current replacement therapy consists of intravenous infusion of protein
concentrate. However, this treatment is costly and inconvenient and
carries with it the risk of blood-borne disease transmission.
Furthermore, bleeds are often treated only after they have occurred,
rather than prophylactically, so that chronic joint damage occurs and the risk of a fatal bleed is always present. Hemophilia is an ideal
model for gene therapy because precise regulation and tissue-specific transgene expression are not required.1,2 A number of
animal models are available including knockout mice and well-described hemophilic dog colonies with phenotypes corresponding to the human disease.3-5 Clinical end points for treatment are well
defined. An increase of factor levels to more than 1% will improve the phenotype of the disease from severe to moderate, with reduced frequency of spontaneous bleeds, and a further increase to more than
5% will result in a mild phenotype; that is, patients would likely
require factor infusion only after severe injury or during surgery.
Currently the most serious complication of treatment is the formation
of inhibitory antibodies to the deficient protein, which occurs with a
frequency of 3% to 4% in patients with hemophilia B.6,7
Inhibitor formation is observed mostly in those patients with extensive
loss of FIX coding information.6,8
Sustained expression of canine FIX (cFIX) in dogs with a missense
mutation has been observed following administration of an adeno-associated virus (AAV) vector into the portal vein for hepatic gene transfer or into skeletal muscle.9-11 The latter
approach is currently being tested in a phase 1 clinical
trial.12 AAV vectors can be produced in a helper
virus-free system, are devoid of any viral gene products, and often
fail to activate antigen-specific cytotoxic T
lymphocytes.13 However, inhibitor formation is still a
frequent complication following intramuscular administration of AAV
vector in hemophilia B mice (with a large F9 gene
deletion) and dogs with a FIX null mutation.14,15
In these animal models, muscle-directed gene therapy was successful
only when combined with transient immunosuppression. Inhibitor
formation in the null mutation dogs has also been described in the
context of lentiviral transfer of a cF9 gene to the
liver.16 These data underscore a potentially serious
immunologic complication for all gene replacement strategies for
treatment of genetic disease, that is, a harmful immune response to the
transgene product in a recipient who is not tolerant to the therapeutic
protein encoded by the donated gene.
In this study, we show sustained correction of canine hemophilia
B following AAV-mediated, liver-directed gene transfer in the context
of a FIX null mutation that is usually associated with a high risk of
inhibitor formation in protein or gene therapy.15,16 These
data are encouraging for gene-based treatment and are directly relevant
to a recently initiated clinical trial of AAV-mediated F9
gene transfer to patients with severe hemophilia B.
AAV vector construction
Experimental animals
Vector administration The animals were premedicated with diazepam (5 mg) or butorphanol (5 mg) or both and atropine (0.6 mg) before anesthetic induction with isoflurane. A midline laparotomy was performed; a mesenteric vein was then isolated and a 20-gauge catheter inserted and tied off with stay sutures. The AAV-(ApoE)4/hAAT-cFIX vector (in a 10-mL volume) was administered by slow bolus infusion (1-2 minutes) and the catheter flushed with 5 to 10 mL heparinized saline before removal and ligation of the mesenteric vein (mesenteric vein administration results in subsequent delivery of the vector to the portal vein for hepatic gene transfer). The abdomen was closed using standard surgical procedures. Butorphanol was administered as needed to provide postoperative analgesia. The dogs were prophylactically administered 90 mL plasma immediately before surgery and 45 mL 8 to 12 hours later. Abnormal reactions or toxicity were not noted following vector administration based on clinical examination and routine clinical pathology tests. Portal vein infusion of vector in hemophilia B dog E34 following midline laparotomy was preformed as described previously.10,11 Vector administration by this method was well tolerated in this animal as well.FIX, coagulation, and antibody assays Blood samples were drawn from hemophilia B dogs as described.15 The whole blood clotting time (WBCT), activated clotting time (ACT), activated partial thromboplastin time (aPTT) of plasma samples, and FIX activity levels were measured as previously reported.9,15 The cFIX antigen levels in plasma samples were determined by enzyme-linked immunosorbent assay (ELISA).9,15 Anti-cFIX was demonstrated by immunocapture assay specific to canine IgG1, IgG2, IgM, and IgA, by Western blot, or by Bethesda assay as described previously.14,15 One Bethesda unit (BU) represents inhibition of normal FIX activity by 50%. The cFIX protein used in these assays was a purified plasma-derived preparation from Enzyme Research Laboratories (South Bend, IN), and all antibodies were purchased from Bethyl Laboratories (Montgomery, TX).15 Antiphospholipid was detected by dilute Russell viper venom time (RVVT). Neutralizing antibodies (NABs) against AAV2 vector particles were measured by inhibition of in vitro LacZ transduction as described.15 The treated animals did not have a pre-existing NAB titer, but all developed NABs to AAV2 after vector administration.DNA analysis Total genomic DNA was isolated from canine liver or spleen tissue using the Easy DNA kit from Invitrogen (Carlsbad, CA). Vector-specific sequences were detected by Southern blot hybridization using a 0.9-kb probe specific to the human 1-antitrypsin
promoter and intron sequences in the AAV vector.
Administration of liver-specific AAV vector results in sustained high-level FIX expression in 3 hemophilia B dogs and transient expression in 1 dog AAV-(ApoE)4/hAAT-cFIX vector was infused into the hepatic circulation of 4 hemophilia B dogs (via mesenteric or portal vein) for hepatocyte-specific expression of cFIX. The vector uses a strong liver-specific promoter/enhancer combination.17 Two animals from the Auburn dog colony (Brad and Semillon) and 1 animal from the UNC-Chapel Hill colony (E34) received vector at a dose of ~1 × 1012 vector genomes (vg)/kg (Table 1). Before treatment none of these animals had detectable circulating cFIX antigen or cFIX activity owing to a FIX null mutation (5-bp deletion plus a C>T transition in the F9 gene resulting in an early stop codon at amino acid residue 146 before the activation peptide of FIX, Auburn dogs) or a FIX missense mutation (G>A resulting in a single amino acid substitution of glutamic acid for Gly379 in the catalytic domain of FIX, UNC dog).3,5
Brad, the first dog treated, also received a total of 180 mL plasma on
day 0 before, during, and after surgical laparotomy and vector
administration and 45 mL daily for the next 4 days. (All other animals
received only ~135 mL plasma before and just after surgery.) By day
14, 10 days after the last plasma infusion, the ACT in Brad was 1.5 minutes (normal range, 1-2 minutes) as compared to 5.5 minutes the day
before vector administration. The ACT has remained in the normal range
for more than 17 months following vector administration (Figure
1B). During the same period, the WBCT was
within the normal range (12.1 ± 2.6 minutes versus > 60 minutes before treatment), and aPTT values (29.4 ± 3.6 seconds) were
significantly shortened from pretreatment times of 79.9 seconds (Figure
1A,C). The cFIX antigen was undetectable before vector administration
but had increased to 317 ng/mL by week 2 and peaked at 907 ng/mL on
week 16 (Figure 1D). Antigen levels of 590 ± 150 ng/mL have
persisted for the duration of the study. Likewise, cFIX activity of
8.6% ± 2.1% of a canine plasma pool has also persisted for the
more than 17-month observation period (Figure 1E and Table 1). The dog
also had a normal cuticle bleed time after treatment (data nor shown).
The other 2 dogs (E34 and Semillon) also showed sustained complete or
nearly complete correction of the WBCT and ACT (not measured in E34)
and substantial correction of the aPTT from more than 60 seconds before
treatment to about 32 to 35 seconds (Table 1 and Figure 1A-C). The cFIX
antigen levels averaged 220 ± 65 ng/mL for Semillon and 262 ± 92
ng/mL for E34 (Figure 1D). FIX activity averaged 4.9% ± 2.6% of
normal canine plasma for Semillon and 5% ± 2.5% for E34 (Figure 1E
and Table 1). Expression was sustained in both animals for more than 6 months in Semillon and more than 7 months in E34 (experiment ongoing).
None of the 3 successfully treated hemophilia B dogs described above had evidence for bleeds following vector administration (a total of 4.3 years of observation for all 3 animals, the UNC dog E34 has been followed for more than 1 year since gene transfer) or liver biopsy (see below). Although bleeding episodes are rarely observed in the Auburn dogs,15 dogs of the UNC-Chapel Hill colony animals receive plasma infusion in response to a bleed on average 6 to 7 times per year, albeit with considerable variation among individual animals.9 A third null mutation dog, Beech, was injected with 3.4 × 1012 vg/kg (~3 times higher vector dose, Table 1). WBCT and ACT values were within the normal range after gene transfer (weeks 2-4), but returned to baseline by week 5 (Figure 1A,B). The aPTT results were consistent with these observations, showing decreasing values through week 4 (without ever achieving a normal value), but returning to a greater than pretreatment value of 90.4 seconds by week 5 (Figure 1C). The cFIX antigen level rose to more than 2 µg/mL by week 4 but had dropped to 13 ng/mL by week 5, and was undetectable by week 6 (Figure 1F). FIX activity showed a similar pattern, rising from 0% to 1.3% by week 2, peaking at 3.0% on week 3, and returning to 0% by week 5 (Figure 1E). As shown below, loss of systemic cFIX expression was due to formation of an inhibitory anti-cFIX that first emerged at week 5. The discrepancy between cFIX antigen levels measured by ELISA and cFIX activity levels in Beech are likely due to the presence of an antiphospholipid antibody in this animal (vide infra) as determined by RVVT assay as described before for a different animal of this colony.15 At 11 weeks after vector administration, Beech developed a fatal intra-abdominal bleed, which, due to a lack of canine bypass reagents such as factor VIIa, could not be treated. Antibody responses against cFIX Beech, the dog with transient FIX expression, developed FIX-specific antibodies concomitant with the loss of FIX antigen and activity. The Bethesda titer increased from 0 (before treatment through week 4) to 4.0 BU at week 5 with a subsequently rising titer (Figure 1F). Anti-cFIX IgG was undetectable in serum from week 0 through 4, but was demonstrated in week 5 and subsequently by Western blot (Figure 2D). Immunocapture assay showed synthesis of IgM at week 4 followed by high titer IgG2 anti-cFIX at week 5 and low titer IgG1 at week 9 (Figure 2E). Brad, Semillon, and E34, the dogs with sustained FIX expression, had no evidence for anti-cFIX by Western blot, immunocapture assay, or Bethesda assay at any time point tested (Figure 2A-C and data not shown). IgA anti-cFIX was not detected in any of the treated animals (data not shown), and no animals had anti-cFIX before treatment.
Lack of vector-related toxicity Serum chemistry panels showed no changes in liver (alanine aminotransferase [ALT]) enzyme tests for dogs Semillon, Beech, and E34 following vector administration (1-3 × 1012 vg/kg, data not shown). None of these animals experienced surgical complications and apparently tolerated vector infusion well. Brad had elevated ALT levels (4 times upper level of normal) during the first 3 to 5 days after vector administration as a result of a surgical complication. The dog had a hematoma at its right hind leg that was present before surgery. The resulting blood loss caused cardiac arrest during the procedure (before vector infusion), which required cardiopulmonary resuscitation including injection of atropine, epinephrine, and sodium bicarbonate to restore cardiac activity and normal circulation. Subsequently, vector was successfully infused without incident. Liver biopsies performed in Brad and Semillon 27 and 32 weeks after vector administration showed normal hepatic tissue without evidence of inflammation or other pathologic changes (Figure 3A-B). Brad and Semillon received a small amount of plasma (~50 mL) prior to liver biopsy and had no subsequent bleeds or other indication for requirement of additional FIX infusion. Hepatic tissue of Beech (necropsy performed 11 weeks after vector administration), the animal with PK deficiency, showed evidence for fibrosis (Figure 3C,F), early cirrhosis, and iron overload (Figure 3I, blue stain) due to chronic hemolytic anemia.
DNA analysis of vector sequences Total genomic DNA from liver and spleen tissue obtained from Beech at necropsy was analyzed by Southern blot hybridization. Using a restriction enzyme (EcoRI) that releases a defined, vector-specific fragment of 0.9 kb, we estimated a gene copy number of 0.1 copies per diploid genome in the liver after comparison of signal strength with plasmid standards (Figure 4B, lanes 1-4). No signal was obtained from splenic DNA (Figure 4B, lane 7). A small amount of episomal double-stranded vector (monomer) was observed in uncut liver DNA (lane 6). Most of the vector was present as a high-molecular-weight species, at least in part arranged as head-to-tail concatemers (digest with enzyme NcoI that cuts once within the vector, thereby releasing a fragment of the size of the unit length of the vector, lane 5). These results are consistent with previous observations for AAV-mediated gene transfer to liver and skeletal muscle.21,22
The FIX-deficient dogs in the Auburn colony have been previously
shown to rapidly produce high-titer inhibitors to cFIX (within 9-14 days) following IV infusion of purified cFIX or transduction of
skeletal muscle with a cFIX-encoded AAV vector (1 × 1012 vg/kg) indicating that the animals are at high risk for inhibitor formation.15 Similarly, inhibitor formation has been
reported in other liver-directed gene transfer strategies in these
dogs.16 This strain of hemophilia B dogs may therefore be
an excellent large animal model to mimic the 3% to 4% of hemophilia B
patients who develop inhibitors in conventional protein replacement
therapy. As is the case in many FIX-deficient patients with inhibitors, these animals are not tolerant to FIX because of the severity of their
mutation, which causes lack of synthesis of cFIX antigen in the
liver.5 Consequently, a neutralizing anti-cFIX response blocked systemic expression in dogs of this colony after
muscle-directed gene therapy at vector doses that conferred sustained
expression of cFIX in hemophilia B dogs with a FIX missense mutation
(inhibitor formation in 2 of 2 null mutation dogs and 0 of 4 missense
mutation dogs at dose Efficacy of hepatic gene transfer and expression In treatment of hemophilia, quantitative differences in factor levels translate into qualitative differences in improvement of the disease phenotype. Previous studies in the missense mutation model of canine hemophilia B have demonstrated sustained expression of up to about 1% of normal levels in muscle- or liver-directed gene therapy with AAV vectors, whereas other gene transfer strategies had yielded only subtherapeutic or transient cFIX expression.23,24 In another recent study on liver-directed gene transfer with AAV, vector doses of 5 × 1012 vg/kg resulted in expression of 0.5% to 4% of normal levels in the missense mutation dogs.11 Compared to the latter, expression levels per delivered vector particle were 5- to 15-fold higher in the studies presented here and 10- to 50-fold higher than in our previous studies on muscle-directed gene transfer in canine hemophilia B. These results are encouraging for clinical application in humans, because high levels of expression are achievable with relatively low vector doses, and the scale-up from the dog model to humans is minimal as opposed to data from mouse studies. Expression levels reported here should be adequate for substantial or nearly complete correction of the bleeding disorder in patients.Lack of inhibitor formation after hepatic gene transfer Use of species-specific transgenes allows us to define the risk of a neutralizing antibody response against expressed FIX antigen. For muscle-directed gene therapy, we have identified the choice of vector, vector dose, and the underlying FIX mutation as important factors that influence the risk of immune responses (Herzog et al9; Fields et al14; Herzog et al15; Fields et al25; and R.W.H., P. A. Fields, T.C.N., K.A.H., unpublished data, May 2000). In this study, we show that an alternative route of administration and choice for target tissue of transgene expression, namely liver, can allow systemic expression of FIX antigen in the context of an unfavorable mutation. Sustained expression of human FIX has been documented in hemophilia B mice with a large F9 gene deletion resulting in absence of endogenous FIX.10 However, hemophilic mice were bred on a C57BL/6 background and have also been successfully treated by systemic administration of a highly immunogenic first-generation adenoviral vector, a result that is not reproducible in other strains of mice.26,27 Nonetheless, route of administration is an important determinant of the risk of a humoral immune response to a secreted transgene product, although the immunologic mechanisms are not understood at this point.26,28,29The results from the Auburn dogs raise the question of whether liver-directed gene transfer may have the potential to induce tolerance to the expressed FIX antigen even in the absence of immune modulation. Induction of immune tolerance by gene transfer will be crucial for treatment of hemophilic patients who had not been extensively treated with coagulation factor antigen, if gene therapy were ever to be used for treatment of children with hemophilia. Based on our results on muscle-directed gene transfer (rapid induction of a T-helper cell-dependent antibody response15,25), one would expect activation of T-cell responses against the transgene product to follow a substantially different mechanism in the context of hepatic gene transfer. This likely reflects differences in the population of antigen-presenting cells in these tissues. For example, liver sinusoidal endothelial cells have been shown to confer antigen-specific CD8+ T-cell tolerance and have also been implemented in CD4+ T-cell tolerance, although the latter is less clear.30,31 Antigen presentation in oral tolerance has been documented to result in immune deviation causing synthesis of IgA instead of IgG and consequently inefficient clearance of the antigen.32 However, we found no evidence for IgA anti-cFIX in serum samples from our treated dogs. Interestingly, both Brad and Semillon have been subjected to liver biopsy, and neither dog has shown an anti-cFIX response indicating that immunologic unresponsiveness was maintained even after an invasive procedure. The liver has been shown to confer antigen-specific tolerance in several experimental models including portal vein tolerance, oral tolerance, and liver allotransplants across incompatible major histocompatibility complex barriers (which cannot easily be achieved for other organs), and may emerge as a preferred target for maintaining tolerance to a systemic transgene product as well.32-35 The AAV vector with reduced potential for inflammation and increased capacity for sustained expression may be ideal for this purpose. It is likely that every combination of target tissue and vector is characterized by a distinct set of immunologic signals. In one dog (Beech), inhibitor formation occurred, although much delayed compared with our results from muscle-directed gene transfer. Beech, unlike the other 2 dogs, also had PK deficiency, which causes chronic hemolytic anemia and an iron overload syndrome. Following necropsy, some level of fibrosis and early stages of cirrhosis were observed in liver tissue as expected in a PK-deficient animal. There was no obvious toxicity/liver pathology that may be attributed to vector treatment. It is unclear whether the PK deficiency, which may be associated with antibodies against red blood cells or antiphospholipid in this particular breed of dogs, poses an additional risk factor for inhibitor formation.15,20 Alternatively, liver pathology secondary to iron overload (and thus altered local cytokine milieu), perhaps in combination with increase in vector dose, may have contributed to inhibitor formation in an animal already inhibitor prone because of the null mutation. Interestingly, elevated liver enzyme levels and other toxicity caused by surgical complications in hemophilia B dog Brad (likely including significant changes in cytokine expression that may provide strong activation or "danger" signals to the immune system) did not predispose to inhibitor formation. This suggests that transient liver toxicity caused by cardiopulmonary arrest, and chronic liver pathology caused by PK deficiency, are not comparable events from an immunologic viewpoint. In conclusion, the data presented here are encouraging for treatment of patients with hemophilia B by in vivo hepatic gene transfer with an AAV vector. Treatment was successful in 3 of 4 large animals with severe disease including 2 of 3 animals of a strain that is prone to inhibitor formation due to a FIX null mutation. Moreover, expression levels were not only therapeutic, but near the curative range at low vector doses.
The authors thank Avigen, a company in which K.A.H. holds equity, for supplying helper plasmids for AAV vector production and assistance with the NAB assay, and D. Ni for technical assistance.
Submitted October 10, 2001; accepted December 5, 2001.
Supported by National Institutes of Health grant R01 HL61921 to K.A.H. R.W.H is supported by a Career Development Award from the National Hemophilia Foundation.
J.D.M. and R.W.H. contributed equally to the study.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Katherine A. High, The Children's Hospital of Philadelphia, Abramson Research Center, Rm 310, 34th St and Civic Center Blvd, Philadelphia, PA 19104; e-mail: high{at}emailchop.edu.
1.
High KA.
Gene transfer as an approach to treating hemophilia.
Circ Res.
2001;88:137-144
2.
Lozier JN, Brinkhous KM.
Gene therapy and the hemophilias.
JAMA.
1994;271:47
3.
Evans JP, Brinkhous KM, Brayer GD, Reisner HW, High KA.
Canine hemophilia B resulting from a point mutation with unusual consequences.
Proc Natl Acad Sci USA.
1989;86:10095-10099
4.
Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW.
A coagulation factor IX-deficient mouse model for human hemophilia B.
Blood.
1997;90:3962-3966
5.
Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr.
A deletion mutation causes hemophilia B in Lhasa Apso dogs.
Blood.
1996;88:3451-3455 6. Giannelli F, Green PM. The molecular basis of hemophilia A and B. In: Lee CA, ed. Clinical Haematology: Haemophilia. Vol 9. London, United Kingdom: Bailliere Tindall; 1996:211-228. 7. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM,Hoyer LW,Lusher JM,Reisner HM,White GC, eds. Advances in Experimental Medicine and Biology. Vol 386. New York: Plenum Press; 1995:79-86. 8. Ljung R, Petrini P, Tengborn L, Sjoerin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol. 2001;113:81-86[CrossRef][Medline] [Order article via Infotrieve]. 9. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63[CrossRef][Medline] [Order article via Infotrieve]. 10. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70[CrossRef][Medline] [Order article via Infotrieve]. 11. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 2000;1:154-158[CrossRef][Medline] [Order article via Infotrieve]. 12. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261[CrossRef][Medline] [Order article via Infotrieve]. 13. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med. 2000;6:17-27[Medline] [Order article via Infotrieve]. 14. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in context of a large factor IX gene deletion. Mol Ther. 2001;4:201-210[CrossRef][Medline] [Order article via Infotrieve]. 15. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CDJ. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4:192-200[CrossRef][Medline] [Order article via Infotrieve]. 16. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther. 1999;10:2091-2107[CrossRef][Medline] [Order article via Infotrieve].
17.
Le M, Okuyama T, Cai S-R, et al.
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
Blood.
1997;89:1254-1259 18. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998;5:938-945[CrossRef][Medline] [Order article via Infotrieve]. 19. Matsushita T, Godwin S, Surosky R, Colosi P. Improvements in AAV vector production: elimination of pseudo-wild type AAV. Proceedings of the 2nd Annual American Society of Gene Therapy. Washington: DC; 1999:2a. 20. Whitney KM, Goodman SA, Bailey EM, Lothrop CD Jr. The molecular basis of canine pyruvate kinase deficiency. Exp Hematol. 1994;22:866-874[Medline] [Order article via Infotrieve]. 21. Miao CH, Snyder RO, Schowalter DB, et al. The kinetics of rAAV integration in the liver. Nat Genet. 1998;19:13-15[CrossRef][Medline] [Order article via Infotrieve]. 22. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098-8108[Abstract].
23.
Kay MA, Rothenberg S, Landen CN, et al.
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Science.
1993;262:117-119
24.
Kay MA, Landen CN, Rothenberg SR, et al.
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
Proc Natl Acad Sci U S A.
1994;91:2353-2357 25. Fields PA, Kowalczyk DW, Arruda VR, et al. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX. Mol Ther. 2000;1:225-235[CrossRef][Medline] [Order article via Infotrieve]. 26. Fields P, Armstrong E, Hagstrom JN, et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 2001;8:354-361[CrossRef][Medline] [Order article via Infotrieve].
27.
Kung J, Hagstrom J, Cass D, et al.
Human F.IX corrects the bleeding diathesis of mice with hemophilia B.
Blood.
1998;91:784-790
28.
Nakai H, Herzog R, Hagstrom JN, et al.
AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver.
Blood.
1998;91:4600-4607
29.
Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW.
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.
Blood.
2001;97:1258-1265 30. Knolle PA, Schmitt E, Jin S, et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology. 1999;116:1428-1440[CrossRef][Medline] [Order article via Infotrieve]. 31. Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6:1348-1354[CrossRef][Medline] [Order article via Infotrieve]. 32. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 1997;18:335-343[CrossRef][Medline] [Order article via Infotrieve]. 33. Knolle PA, Gerken G. Local control of the immune response in the liver. Immunol Rev. 2000;174:21-34[CrossRef][Medline] [Order article via Infotrieve]. 34. Pastore L, Morral N, Zhou H, et al. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther. 1999;10:1773-1781[CrossRef][Medline] [Order article via Infotrieve]. 35. Vemuru RP, Davidson A, Aragona E, Chowdhury JR, Burk RD, Gupta S. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy. FASEB J. 1992;6:2836-2842[Abstract].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Mingozzi, J. J. Meulenberg, D. J. Hui, E. Basner-Tschakarjan, N. C. Hasbrouck, S. A. Edmonson, N. A. Hutnick, M. R. Betts, J. J. Kastelein, E. S. Stroes, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells Blood, September 3, 2009; 114(10): 2077 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Lai, M. J. Estcourt, M. Wikstrom, R. P. Himbeck, N. L. Barnett, M. Brankov, L. B. G. Tee, S. A. Dunlop, M. A. Degli-Esposti, and E. P. Rakoczy rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4279 - 4287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Margaritis, E. Roy, M. N. Aljamali, H. D. Downey, U. Giger, S. Zhou, E. Merricks, A. Dillow, M. Ezban, T. C. Nichols, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa Blood, April 16, 2009; 113(16): 3682 - 3689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Niemeyer, R. W. Herzog, J. Mount, V. R. Arruda, D. M. Tillson, J. Hathcock, F. W. van Ginkel, K. A. High, and C. D. Lothrop Jr Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy Blood, January 22, 2009; 113(4): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C.S. Tam, A.-S. Kiang, A. Kennan, P. F. Kenna, N. Chadderton, M. Ader, A. Palfi, A. Aherne, C. Ayuso, M. Campbell, et al. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10) Hum. Mol. Genet., July 15, 2008; 17(14): 2084 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mingozzi, N. C. Hasbrouck, E. Basner-Tschakarjan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver Blood, October 1, 2007; 110(7): 2334 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Cao, E. Dobrzynski, L. Wang, S. Nayak, B. Mingle, C. Terhorst, and R. W. Herzog Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer Blood, August 15, 2007; 110(4): 1132 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, M. Hirsch, A. Asokan, B. Zeithaml, H. Ma, T. Kafri, and R. J. Samulski Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo J. Virol., July 15, 2007; 81(14): 7540 - 7547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. High Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia Hematology, January 1, 2007; 2007(1): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jiang, L. B. Couto, S. Patarroyo-White, T. Liu, D. Nagy, J. A. Vargas, S. Zhou, C. D. Scallan, J. Sommer, S. Vijay, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Blood, November 15, 2006; 108(10): 3321 - 3328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kitajima, D. H.L. Marchadier, G. C. Miller, G.-p. Gao, J. M. Wilson, and D. J. Rader Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8 Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1852 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Cao, E. Armstrong, A. Schlachterman, L. Wang, D. K. Okita, B. Conti-Fine, K. A. High, and R. W. Herzog Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX Blood, July 15, 2006; 108(2): 480 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs Blood, July 1, 2006; 108(1): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dobrzynski, J. C. Fitzgerald, O. Cao, F. Mingozzi, L. Wang, and R. W. Herzog Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells PNAS, March 21, 2006; 103(12): 4592 - 4597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Ostrander and R. K. Wayne The canine genome Genome Res., December 1, 2005; 15(12): 1706 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dobrzynski and R. W. Herzog Tolerance Induction by Viral In Vivo Gene Transfer Clin. Med. Res., November 1, 2005; 3(4): 234 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aguirre-Hernandez and D. R. Sargan Evaluation of Candidate Genes in the Absence of Positional Information: A Poor Bet on a Blind Dog! J. Hered., September 1, 2005; 96(5): 475 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, E. Dobrzynski, A. Schlachterman, O. Cao, and R. W. Herzog Systemic protein delivery by muscle-gene transfer is limited by a local immune response Blood, June 1, 2005; 105(11): 4226 - 4234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Arruda, H. H. Stedman, T. C. Nichols, M. E. Haskins, M. Nicholson, R. W. Herzog, L. B. Couto, and K. A. High Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model Blood, May 1, 2005; 105(9): 3458 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, R. Calcedo, T. C. Nichols, D. A. Bellinger, A. Dillow, I. M. Verma, and J. M. Wilson Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy Blood, April 15, 2005; 105(8): 3079 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Rivera, G.-p. Gao, R. L. Grant, M. A. Schnell, P. W. Zoltick, L. W. Rozamus, T. Clackson, and J. M. Wilson Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer Blood, February 15, 2005; 105(4): 1424 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kikuchi, A. D. McDonald, T. Sasano, and J. K. Donahue Targeted Modification of Atrial Electrophysiology by Homogeneous Transmural Atrial Gene Transfer Circulation, January 25, 2005; 111(3): 264 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kashiwakura, K. Tamayose, K. Iwabuchi, Y. Hirai, T. Shimada, K. Matsumoto, T. Nakamura, M. Watanabe, K. Oshimi, and H. Daida Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection J. Virol., January 1, 2005; 79(1): 609 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bauer, A. D. McDonald, K. Nasir, L. Peller, J. J. Rade, J. M. Miller, A. W. Heldman, and J. K. Donahue Inhibitory G Protein Overexpression Provides Physiologically Relevant Heart Rate Control in Persistent Atrial Fibrillation Circulation, November 9, 2004; 110(19): 3115 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Waddington, M. S. Nivsarkar, A. R. Mistry, S. M. K. Buckley, G. Kemball-Cook, K. L. Mosley, K. Mitrophanous, P. Radcliffe, M. V. Holder, M. Brittan, et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy Blood, November 1, 2004; 104(9): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene Blood, November 1, 2004; 104(9): 2767 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. VandenDriessche Liver gene transfer keeps immune system in check Blood, August 15, 2004; 104(4): 910 - 911. [Full Text] [PDF]
|
|
|
|
|
|
E. Dobrzynski, F. Mingozzi, Y.-L. Liu, E. Bendo, O. Cao, L. Wang, and R. W. Herzog Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer Blood, August 15, 2004; 104(4): 969 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Follenzi, M. Battaglia, A. Lombardo, A. Annoni, M. G. Roncarolo, and L. Naldini Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice Blood, May 15, 2004; 103(10): 3700 - 3709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, L. Xu, M. E. Haskins, and K. Parker Ponder Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs Blood, January 1, 2004; 103(1): 143 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Scallan, T. Liu, A. E. Parker, S. L. Patarroyo-White, H. Chen, H. Jiang, J. Vargas, D. Nagy, S. K. Powell, J. F. Wright, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII Blood, December 1, 2003; 102(12): 3919 - 3926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ehrhardt, H. Xu, A. M. Dillow, D. A. Bellinger, T. C. Nichols, and M. A. Kay A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia Blood, October 1, 2003; 102(7): 2403 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. VandenDriessche Challenges and progress in gene therapy for hemophilia A Blood, September 15, 2003; 102(6): 1938 - 1939. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Scallan, D. Lillicrap, H. Jiang, X. Qian, S. L. Patarroyo-White, A. E. Parker, T. Liu, J. Vargas, D. Nagy, S. K. Powell, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector Blood, September 15, 2003; 102(6): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Davidoff, C. Y. C. Ng, J. Zhou, Y. Spence, and A. C. Nathwani Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway Blood, July 15, 2003; 102(2): 480 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Xu, C. Gao, M. S. Sands, S.-R. Cai, T. C. Nichols, D. A. Bellinger, R. A. Raymer, S. McCorquodale, and K. P. Ponder Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B Blood, May 15, 2003; 101(10): 3924 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fraser, D. G. Le Couteur, A. Warren, V. C. Cogger, P. Bertolino, M. Smith, K. A. High, R. Herzog, and V. Arruda The liver sieve and gene therapy Blood, April 15, 2003; 101(8): 3338 - 3338. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood, April 15, 2003; 101(8): 2963 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Waddington, S. M. K. Buckley, M. Nivsarkar, S. Jezzard, H. Schneider, T. Dahse, G. Kemball-Cook, M. Miah, N. Tucker, M. J. Dallman, et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor Blood, February 15, 2003; 101(4): 1359 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Wang, K. G. Rendahl, W. C. Manning, D. Quiroz, M. Coyne, and S. S. Miller AAV-Mediated Expression of Vascular Endothelial Growth Factor Induces Choroidal Neovascularization in Rat Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 781 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Rick, C. E. Walsh, and N. S. Key Congenital Bleeding Disorders Hematology, January 1, 2003; 2003(1): 559 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mingozzi, J. Schuttrumpf, V. R. Arruda, Y. Liu, Y.-L. Liu, K. A. High, W. Xiao, and R. W. Herzog Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector J. Virol., September 11, 2002; 76(20): 10497 - 10502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Nathwani, A. M. Davidoff, H. Hanawa, Y. Hu, F. A. Hoffer, A. Nikanorov, C. Slaughter, C. Y. C. Ng, J. Zhou, J. N. Lozier, et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques Blood, August 13, 2002; 100(5): 1662 - 1669. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-globin/CMV intron, the
cFIX complementary DNA (cDNA), and the human growth hormone
polyadenylation (hGH poly A) signal as described.
80°C prior use. Vector titers were determined by quantitative slot
blot hybridization. The Limulus amoebocyte lysate assay (Sigma, St
Louis, MO) was performed to confirm absence of detectable endotoxin in
vector preparations.
, blue line), Semillion (1 × 10
,
green line), E34 (
, red line, ACT was not measured in this dog), and
Beech (3 × 10
, black line, data for Beech
are omitted in graph D). Vector was administered into the mesenteric
(Brad, Semillon, Beech) or portal vein (E34) for liver-directed gene
transfer. The ranges for coagulation times in normal, healthy dogs are
6 to 10 minutes (WBCT), 1 to 2 minutes (ACT), and 18 to 20 seconds
(aPTT). In hemophilia B dogs they are more than 60 minutes (WBCT), more
than 4 minutes (ACT), and more than 60 seconds (aPTT). (F) The cFIX
antigen levels (
3 × 10